Sign in
OABI Stock Price, Chart, Stats & News
OmniAb, Inc.
Save
OmniAb, Inc. (OABI) does not currently pay a dividend.
694.42M
Market cap
–
Current P/E
–
Forward P/E
OABI chart
Fundamentals
Gross margin | 73.45% |
Operating margin | -383.15% |
Pretax margin | -342.72% |
Net margin | -347.04% |
Effective tax rate | -1.26% |
ROA | -21.53% |
ROE | -23.99% |
D/E | 0.08x |
Interest coverage ratio | – |
OABI valuation
P/E | – |
P/S | 9.21x |
P/B | 0.72x |
P/CF | -5.29x |
P/FCF | -4.64x |
P/OCF | -5.29x |
PEG | -1.73x |
EV multiple | -3.74x |
About
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse.
Similar securities
Based on sector and market capitalization
Report issue